Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Table 2 Comparison of soluble interleukin-2 receptor, interleukin-17, and interleukin-35 levels in each group (mean ± SD)

Group	sIL-2R (U/mL)		IL-17 (pg/mL)		IL-35 (pg/mL)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	546.78 ± 36.67	435.26 ± 26.47	15.67 ± 2.44	10.27 ± 2.32	56.59 ± 7.23	68.78 ± 6.34
Observation (n = 75)	545.56 ± 34.12	359.56 ± 21.98	14.78 ± 2.65	6.79 ± 2.78	57.67 ± 7.15	94.98 ± 6.78
t	0.190	17.370	1.898	7.313	0.061	21.716
P value	0.849	< 0.001	0.060	< 0.001	0.951	< 0.001

sIL-2R: Soluble interleukin-2 receptor; IL-17: Interleukin-17; IL-35: Interleukin-35.